Immunogenic Cell Death as a Target for Combination Therapies in Solid Tumors: A Systematic Review Toward a New Paradigm in Immuno-Oncology
Cureus · 11.06.2025
DOI: 10.7759/cureus.85776 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cureus, erschienen am 11.06.2025. Verfasst von Imad Barjij und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine and Pharmacy of Rabat, National Institute of Oncology, Ibn Sina University Hospital, Mohammed V U…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Immunogenic cell death (ICD) represents a distinct form of regulated cell death that triggers robust antitumor immune responses through the release of damage-associated molecular patterns (DAMPs) such as calreticulin (CRT), extracellular adenosine triphosphate (ATP), and high-mobility group box 1 protein (HMGB1). While ICD has emerged as a promising strategy to enhance cancer immunotherapy, its integration into therapeutic regimens remains fragmented. This systematic review aimed to synthesize the experimental evidence on ICD-inducing treatments in solid tumors and assess the convergence of mechanistic pathways and combination strategies. A comprehensive literature search identified 14 eligible studies published between 2010 and 2025, including preclinical in vitro and in vivo investigations of radiotherapy, chemotherapy, photodynamic therapy (PDT), oncolytic virotherapy, and redox- or lysosome-targeted agents. Despite mechanistic diversity, most interventions converged on shared cellular stress responses, notably endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) production, leading to DAMP exposure and dendritic cell maturation. Eight studies incorporated immune checkpoint inhibitors, revealing synergistic antitumor effects and immune memory enhancement. While most studies demonstrated in vivo efficacy, two relied solely on in vitro or ex vivo models. The risk of bias was low in the majority of cases. Collectively, the evidence supports ICD as a central immunologic interface capable of transforming cytotoxic therapies into immune-activating treatments. Future clinical research should prioritize ICD biomarker validation, optimization of treatment timing, and development of personalized ICD-based combination regimens. These findings reinforce the potential of ICD to serve as a unifying framework in the next generation of cancer immunotherapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Faculty of Medicine and Pharmacy of Rabat, National Institute of Oncology, Ibn Sina University Hospital, Mohammed V University, Rabat, MAR.
- Department of Medical Oncology, Regional Oncology Center of Laâyoune, Regional Hospital Center of Laâyoune, Laâyoune, MAR.
Zitieren
APA
Barjij, I., & Meliani, M. (2025). Immunogenic Cell Death as a Target for Combination Therapies in Solid Tumors: A Systematic Review Toward a New Paradigm in Immuno-Oncology. Cureus. https://doi.org/10.7759/cureus.85776
Vancouver
Barjij I, Meliani M. Immunogenic Cell Death as a Target for Combination Therapies in Solid Tumors: A Systematic Review Toward a New Paradigm in Immuno-Oncology. Cureus. 2025. doi:10.7759/cureus.85776
BibTeX
@article{Barjij2025,
author = {Barjij, Imad and Meliani, Meryem},
title = {Immunogenic Cell Death as a Target for Combination Therapies in Solid Tumors: A Systematic Review Toward a New Paradigm in Immuno-Oncology},
journal = {Cureus},
year = {2025},
doi = {10.7759/cureus.85776}
}
EUVIMED